News | September 18, 2009

vProtect Luminal Shield Discussed at TCT as New Treatment for Soft Coronary Lesions

September 18, 2009 – Following the recent CE mark certification of the vProtect Luminal Shield, the novel self-expanding coronary stent system will be the focus of scientific presentations and roundtable discussions on lesion-specific therapy for coronary artery disease at TCT 2009, Sept. 21-25, in San Francisco. The vPredict Optical Catheter System, a diagnostic device to detect plaque composition, also from Prescient Medical, will also be featured in several presentations.

All sessions will be held at the Moscone Center.

• 8 a.m. to 6:45 p.m., Monday, Sept. 21, room 131 – Both devices will be discussed in the day-long scientific symposium "Vulnerable Plaque: Emerging Direction for Diagnosis and Treatment." Professor Patrick W. Serruys of Erasmus Medical Center in Rotterdam will discuss clinical experience with the vProtect Luminal Shield in stabilizing vulnerable plaque at 5:05 p.m. "Recent developments in the field of vulnerable plaque are very exciting," said Dr. Serruys. "We are finally making progress in characterizing, understanding, and potentially treating these lesions." Other key presentations include discussions of preclinical and clinical studies by Juan Granada, M.D., of the Cardiovascular Research Foundation, and Giuseppe Sangiorgi, M.D., director of interventional cardiology at the University of Rome at 9 a.m., 3:30 p.m., and 4:45 p.m.

• 4-4:20 p.m. Wednesday, Sept. 23, room 134 – Dr. Granada, will present key findings relating to the low-injury self-expanding design of the vProtect Luminal Shield during "Coronary Stent Design and Device Development."

• 4:45-4:55 p.m. Thursday, Sept. 24, room 133 – Dr. Granada will present additional data on the vProtect Luminal Shield during "The Re-Emergence of Nitinol Self-Expanding Coronary Stents," a special session dedicated to exploring the re-emergence of self-expanding coronary stents led by the vProtect Luminal Shield. "It has become clear that stent designs and materials should be tailored to the pathophysiology of the lesion to be treated,” Dr. Granada said. “The Shield is designed specifically to minimize arterial injury and its consequences, making it ideal for softer plaques."

For more information: www.prescientmedical.com

Related Content

FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter
News | Chronic Total Occlusion (CTO)| June 28, 2017
June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
Overlay Init